Siemens Healthineers (SHL) PT Set at €37.00 by Deutsche Bank

Deutsche Bank set a €37.00 ($43.02) price target on Siemens Healthineers (ETR:SHL) in a report published on Tuesday. The brokerage currently has a neutral rating on the stock.

Several other research analysts have also commented on SHL. Morgan Stanley set a €34.00 ($39.53) price target on Siemens Healthineers and gave the stock a neutral rating in a research report on Monday, September 17th. Oddo Bhf set a €39.00 ($45.35) price target on Siemens Healthineers and gave the stock a neutral rating in a research report on Friday, September 21st. Sanford C. Bernstein set a €41.00 ($47.67) price target on Siemens Healthineers and gave the stock a neutral rating in a research report on Tuesday, September 25th. Goldman Sachs Group set a €34.50 ($40.12) price target on Siemens Healthineers and gave the stock a neutral rating in a research report on Tuesday, September 25th. Finally, Citigroup set a €42.50 ($49.42) price target on Siemens Healthineers and gave the stock a buy rating in a research report on Thursday, September 27th. Fourteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of €38.28 ($44.52).

SHL opened at €35.25 ($40.99) on Tuesday.

Siemens Healthineers Company Profile

Siemens Healthineers AG develops, manufactures, and distributes imaging, advanced therapies, and diagnostic products and services to healthcare providers worldwide. It operates in three operating segments: Imaging, Advanced Therapies, and Diagnostics. The Imaging segment provides diagnostic imaging and ultrasound systems and solutions.

Featured Story: Short Selling

Analyst Recommendations for Siemens Healthineers (ETR:SHL)

Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply